LIVN.NASDAQLivanova PLC

Form 4: LivaNova PLC Director Daniel Jeffrey Moore Executes Option and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4


Director Daniel Jeffrey Moore exercised options and sold LivaNova PLC shares under a pre-arranged 10b5-1 trading plan.

Summary

  • On June 3, 2024, Daniel Jeffrey Moore, a director of LivaNova PLC, exercised an option to purchase 56,623 ordinary shares at a price of $57.39 per share.
  • The option exercise was conducted under a Rule 10b5-1 plan adopted on May 25, 2021.
  • Moore also sold 54,578 ordinary shares at a weighted average price of $60.075, with prices ranging from $59.75 to $60.610.
  • Additionally, 2,045 ordinary shares were sold at a weighted average price of $61.086, with prices ranging from $60.829 to $61.290.
  • These sales were also executed under the same Rule 10b5-1 plan.
  • Following these transactions, Moore directly owns 27,534 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Positives

  • The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating no insider information was used.

Industry Context

Directors and officers routinely use 10b5-1 plans to sell company stock to avoid accusations of insider trading. This filing indicates standard practice.

Comparison to Industry Standards

  • Executive compensation packages often include stock options as a form of long-term incentive.
  • The use of 10b5-1 trading plans is a common practice among corporate insiders to manage their stock sales in compliance with securities laws.
  • Comparable companies such as Medtronic or Boston Scientific also see similar filings from their executives related to stock options and sales.

Key Dates

DateDescription
10/19/2015Original date of option grant.
10/22/2015Form 3 filed on behalf of the reporting person.
05/25/2021Date of adoption of Rule 10b5-1 Plan.
06/03/2024Date of transaction (option exercise and share sales).
06/05/2024Date of signature on the Form 4.
06/15/2024Expiration date of the option.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.